FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a pharmaceutical composition in the form of a solid gelatine capsule containing fenosanic acid and excipients containing mg per one capsule: fenosanic acid or its pharmaceutically acceptable salt 100–200; baking powder 40–280; binder 2–100; lubricant 0.1–4.5.
EFFECT: technical result of the present invention is enabling industrial production of a pharmaceutical composition in form of a solid gelatine capsule containing fenosanic acid.
6 cl, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING FENOSANIC ACID | 2019 |
|
RU2731536C1 |
| STABLE PHARMACEUTICAL COMPOSITION CONTAINING WATER-SOLUBLE VINFLUNINE SALT | 2008 |
|
RU2462248C2 |
| STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DGAT1 INHIBITOR | 2011 |
|
RU2595866C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING IBUPROFEN AND DOMPERIDONE FOR MIGRAINE TREATMENT | 1998 |
|
RU2195935C2 |
| ENCAPSULATED DOSAGE FORM, CONTAINING MONTELUKAST AND LEVOCETIRIZINE | 2012 |
|
RU2606857C2 |
| LENALIDOMIDE TABLET COMPOSITION FOR ORAL ADMINISTRATION | 2017 |
|
RU2725074C1 |
| STABLE PHARMACEUTICAL COMPOSITION OF WATER-SOLUBLE SALT OF VINORELBINE | 2008 |
|
RU2476208C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | 2010 |
|
RU2533560C2 |
| ORAL COMPOSITIONS OF CARDIAC SARCOMERE INHIBITORS | 2020 |
|
RU2823999C2 |
Authors
Dates
2020-11-17—Published
2019-07-30—Filed